vorinostat has been researched along with African Lymphoma in 5 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A panel of rituximab-chemotherapy-sensitive (RSCL) and rituximab-chemotherapy-resistant cell lines (RRCL) and primary tumor cells isolated from relapsed/refractory B cell lymphoma patients were exposed to escalating doses of vorinostat." | 7.83 | Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents. ( Czuczman, MS; Gu, JJ; Guo, Y; Hernandez-Ilizaliturri, FJ; Mavis, C; Xue, K; Zhang, Q, 2016) |
| "A panel of rituximab-chemotherapy-sensitive (RSCL) and rituximab-chemotherapy-resistant cell lines (RRCL) and primary tumor cells isolated from relapsed/refractory B cell lymphoma patients were exposed to escalating doses of vorinostat." | 3.83 | Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents. ( Czuczman, MS; Gu, JJ; Guo, Y; Hernandez-Ilizaliturri, FJ; Mavis, C; Xue, K; Zhang, Q, 2016) |
| " We found that 4 histone deacetylase inhibitors, trichostatin A (TSA), sodium butyrate (SB), valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA), all significantly induced EBV lytic cycle in EBV-positive gastric carcinoma cells (AGS/BX1, latency II) but only weakly induced in Burkitt lymphoma cells (AK2003, latency I) and did not induce in lymphoblastoid cells (LCLs, latency III)." | 3.76 | Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death. ( Chiang, AK; Hui, KF, 2010) |
| "The treatment rate of Burkitt lymphoma (BL) is still low in low-income countries and among elderly patients." | 1.91 | Network and Computational Drug Repurposing Analysis for c-Myc Inhibition in Burkitt Lymphoma. ( Lee, Y; Nam, S, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, Z | 1 |
| Shen, M | 1 |
| Tang, M | 1 |
| Zhang, W | 1 |
| Cui, X | 1 |
| Zhang, Z | 1 |
| Pei, H | 1 |
| Li, Y | 1 |
| Hu, M | 1 |
| Bai, P | 1 |
| Chen, L | 1 |
| Lee, Y | 1 |
| Nam, S | 1 |
| Xue, K | 1 |
| Gu, JJ | 1 |
| Zhang, Q | 1 |
| Mavis, C | 1 |
| Hernandez-Ilizaliturri, FJ | 1 |
| Czuczman, MS | 1 |
| Guo, Y | 1 |
| Hui, KF | 1 |
| Chiang, AK | 1 |
| Tsapis, M | 1 |
| Lieb, M | 1 |
| Manzo, F | 1 |
| Shankaranarayanan, P | 1 |
| Herbrecht, R | 1 |
| Lutz, P | 1 |
| Gronemeyer, H | 1 |
5 other studies available for vorinostat and African Lymphoma
| Article | Year |
|---|---|
Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Burkitt Lymphoma; Cell Line, Tumor; Cell Pro | 2019 |
Network and Computational Drug Repurposing Analysis for c-Myc Inhibition in Burkitt Lymphoma.
Topics: Aged; Burkitt Lymphoma; Drug Repositioning; Humans; Proto-Oncogene Proteins c-myc; Signal Transducti | 2023 |
Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Burkitt Lymphoma; Cell Growth Processes; | 2016 |
Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Burkitt Lymphoma; Butyrates; Carcinoma; Cell Cy | 2010 |
HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway.
Topics: Apoptosis; Benzamides; Burkitt Lymphoma; Cyclin-Dependent Kinase Inhibitor p21; Dexamethasone; Drug | 2007 |